PRESS RELEASE 2023
US Press Releases > PRESS RELEASE 2023
-
Ferring Pharmaceuticals Announces Availability of REBYOTA™ (fecal microbiota, live – jslm) – the First and Only FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrence of C. diff Infection in Adults
REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection REBYOTA is now available by prescription in the United States Ferring is committed to maki...